Meloxivet

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

meloxicam

Available from:

Eli Lilly and Company Limited 

ATC code:

QM01AC06

INN (International Name):

meloxicam

Therapeutic group:

Klieb

Therapeutic area:

Sistema musculo-skeletali

Therapeutic indications:

Tnaqqis ta 'infjammazzjoni u uġigħ kemm fid-disturbi muskuloskeletali akuti kif ukoll kroniċi.

Product summary:

Revision: 5

Authorization status:

Irtirat

Authorization date:

2007-11-14

Patient Information leaflet

                                Prodott mediċinali li m’għadux awtorizzat
24
B. FULJETT TA’ TAGĦRIF FIL-PAKKETT
Prodott mediċinali li m’għadux awtorizzat
25
FULJETT TA’ TAGĦRIF FIL-PAKKETT GĦAL:
MELOXIVET 0.5 MG/ML SUSPENSJONI ORALI GĦALL-KLIEB
1.
L-ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-KUMMERĊ, U
L-ISEM U L-INDIRIZZ TAS-SID TA’ L-AWTORIZZAZZJONI TAL-MANIFATTURA
RESPONSABBLI LI JĦALLI L-KONSENJA TMUR FIS-SUQ , JEKK DIFFERENTI
Sid l-Awtorizzazzjoni tal-Kummerċ:
Eli Lilly and Company Limited
Elanco Animal Health
Lilly House, Priestley Road
Basingstoke
Hampshire RG24 9NL
Ir-Renju Unit
Manifattur li jħalli l-konsenja tmur fis-suq
:
Lusomedicamenta S.A.
Estrada Consiglieri Pedroso, 69 B Queluz de Baixo
2730-055 Barcarena
Il-Portugall
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Meloxivet 0.5 mg/ml suspensjoni orali għall-klieb
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Millilitru fih:
Meloxicam
0.5 mg
Sodium benzoate
1 mg
4.
INDIKAZZJONI(JIET)
Għas-solliev ta’ infjammazzjoni u wġigħ f’disturbi
muskolu-skeletriċi kemm akuti kif ukoll kroniku
fil-klieb.
5.
KONTRA-INDIKAZZJONIJIET
Tagħtix Meloxivet:
-
jekk il-kelba tiegħek hi tqila jew qed tredda’
-
jekk il-kelb tiegħek qed ibati minn disturbi gastrointestinali, bħal
irritazzjoni u emorraġija,
indeboliment fil-funzjoni epatika, kardijaka jew renali u disturbi
emorraġiċi.
-
jekk il-kelb tiegħek għandu sensittività eċċessiva (allerġiku)
għal sustanza attiva jew għal xi
waħda mis-sustanzi l oħra.
-
jekk il-kelb tiegħek għandu inqas minn 6 ġimgħat
Prodott mediċinali li m’għadux awtorizzat
26
6.
EFFETTI MHUX MIXTIEQA
Reazzjonijiet avversi tipiċi ta’ NSAIDs bħal nuqqas ta’ aptit,
rimettar, dijarea, demm moħbi fl-
ippurgar, letarġija u insuffiċjenza tal-kliewi ġew irrappurtati xi
kultant. F’każijiet rari ħafna dijarea
emorraġika, ematemesi, ulċerazzjoni gastrointestinali u livelli
għolja ta’ enzimi tal-fwied ġew
irrappurtati.
Dawn l-effetti sekondarji ġeneralment iseħħu fi żmien l-ewwel
ġimgħa 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Prodott mediċinali li m’għadux awtorizzat
1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
Prodott mediċinali li m’għadux awtorizzat
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Meloxivet 0.5 mg/ml suspensjoni orali għall-klieb
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Millilitru fih:
SUSTANZA ATTIVA:
Meloxicam
0.5 mg
SUSTANZA MHUX ATTIVA:
Sodium benzoate
1 mg
Għal-lista sħiħa ta’ l-ingredjenti (mhux attivi), ara s-sezzjoni
6.1.
3.
GĦAMLA FARMAĊEWTIKA
Suspensjoni orali. Suspensjoni opaka minn bajda sa safranija.
_ _
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb.
4.2
INDIKAZZJONIJIET GĦALL-UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Għas-solliev ta’ infjammazzjoni u wġigħ f’disturbi
muskolu-skeletriċi kemm akuti kif ukoll kroniku
fil-klieb.
4.3
KONTRA-INDIKAZZJONIJIET
Tużax fuq klieb tqal jew li qed ireddgħu.
Tużax fuq klieb li jkunu jbatu minn disturbi gastrointestinali, bħal
irritazzjoni u emorraġija,
indeboliment fil-funzjoni epatika, kardijaka jew renali u disturbi
emorraġiċi.
Tużax f’ka
żi
jiet ta’ sensittività għall-ingredjent attiv; ingredjenti miżjuda
jew ingredjenti oħra.
Tużax fuq klieb li jkollhom inqas minn 6 ġimgħat.
4.4
TWISSIJIET SPEĊJALI
Xejn.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU FL-ANNIMALI
Evita l-użu fi kwalunkwe annimal li jkun deidratat, ipovolaemiku jew
ipotensiv, għax hemm riskju
potenzjali ta’ tossiċità tal-kliewi.
Prodott mediċinali li m’għadux awtorizzat
3
PREKAWZJONIJIET SPEĊJALI LI GĦANDHOM JITTIEĦDU MILL-PERSUNA LI
TAMMINISTRA L-PRODOTT MEDIĊINALI
VETERINARJU LILL-ANNIMALI
Nies li hu magħruf li għandhom sensittività eċċessiva għal
mediċini mhux sterojdi kontra
l-infjammazzjoni (NSAIDs) għandhom jevitaw li jmissu mal-prodott
mediċinali veterinarju.
F’każ li tibla’ l-prodott b’mod aċċidentali, fittex tabib
mal-ewwel u qis li turih il-fuljett ta’
informazzjoni jew it-tikketta.
4.6
EFFETTI MHUX MIXTIEQA (FR
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-05-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-05-2018
Public Assessment Report Public Assessment Report Bulgarian 28-05-2018
Patient Information leaflet Patient Information leaflet Spanish 28-05-2018
Public Assessment Report Public Assessment Report Spanish 28-05-2018
Patient Information leaflet Patient Information leaflet Czech 28-05-2018
Public Assessment Report Public Assessment Report Czech 28-05-2018
Patient Information leaflet Patient Information leaflet Danish 28-05-2018
Public Assessment Report Public Assessment Report Danish 28-05-2018
Patient Information leaflet Patient Information leaflet German 28-05-2018
Public Assessment Report Public Assessment Report German 28-05-2018
Patient Information leaflet Patient Information leaflet Estonian 28-05-2018
Public Assessment Report Public Assessment Report Estonian 28-05-2018
Patient Information leaflet Patient Information leaflet Greek 28-05-2018
Public Assessment Report Public Assessment Report Greek 28-05-2018
Patient Information leaflet Patient Information leaflet English 28-05-2018
Public Assessment Report Public Assessment Report English 28-05-2018
Patient Information leaflet Patient Information leaflet French 28-05-2018
Public Assessment Report Public Assessment Report French 28-05-2018
Patient Information leaflet Patient Information leaflet Italian 28-05-2018
Public Assessment Report Public Assessment Report Italian 28-05-2018
Patient Information leaflet Patient Information leaflet Latvian 28-05-2018
Public Assessment Report Public Assessment Report Latvian 28-05-2018
Patient Information leaflet Patient Information leaflet Lithuanian 28-05-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-05-2018
Public Assessment Report Public Assessment Report Lithuanian 28-05-2018
Patient Information leaflet Patient Information leaflet Hungarian 28-05-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 28-05-2018
Public Assessment Report Public Assessment Report Hungarian 28-05-2018
Patient Information leaflet Patient Information leaflet Dutch 28-05-2018
Public Assessment Report Public Assessment Report Dutch 28-05-2018
Patient Information leaflet Patient Information leaflet Polish 28-05-2018
Public Assessment Report Public Assessment Report Polish 28-05-2018
Patient Information leaflet Patient Information leaflet Portuguese 28-05-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 28-05-2018
Public Assessment Report Public Assessment Report Portuguese 28-05-2018
Patient Information leaflet Patient Information leaflet Romanian 28-05-2018
Public Assessment Report Public Assessment Report Romanian 28-05-2018
Patient Information leaflet Patient Information leaflet Slovak 28-05-2018
Public Assessment Report Public Assessment Report Slovak 28-05-2018
Patient Information leaflet Patient Information leaflet Slovenian 28-05-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 28-05-2018
Public Assessment Report Public Assessment Report Slovenian 28-05-2018
Patient Information leaflet Patient Information leaflet Finnish 28-05-2018
Public Assessment Report Public Assessment Report Finnish 28-05-2018
Patient Information leaflet Patient Information leaflet Swedish 28-05-2018
Public Assessment Report Public Assessment Report Swedish 28-05-2018
Patient Information leaflet Patient Information leaflet Norwegian 28-05-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 28-05-2018
Patient Information leaflet Patient Information leaflet Icelandic 28-05-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 28-05-2018
Patient Information leaflet Patient Information leaflet Croatian 28-05-2018

Search alerts related to this product

View documents history